Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹7,657 Cr
Revenue (TTM)
₹2,115 Cr
Net Profit (TTM)
₹272 Cr
ROE
13.1 %
ROCE
16.7 %
P/E Ratio
28.1
P/B Ratio
3.8
Industry P/E
41.45
EV/EBITDA
17
Div. Yield
0.6 %
Debt to Equity
0.1
Book Value
₹219.6
EPS
₹30.1
Face value
5
Shares outstanding
90,634,624
CFO
₹422.75 Cr
EBITDA
₹933.34 Cr
Net Profit
₹532.62 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aarti Pharmalabs
| 23.2 | 15.2 | 5.4 | 37.4 | -- | -- | -- |
|
BSE Healthcare
| -5.8 | 2.0 | 6.1 | 19.3 | 24.1 | 23.4 | 9.7 |
|
BSE Small Cap
| -6.1 | 7.3 | 13.1 | 7.2 | 25.8 | 37.8 | 16.5 |
|
Company
|
2024
|
|---|---|
|
Aarti Pharmalabs
| 35.8 |
|
BSE Small Cap
| 29.0 |
|
BSE Healthcare
| 43.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aarti Pharmalabs
|
845.4 | 7,657.3 | 2,115.1 | 272.4 | 17.8 | 14.2 | 28.1 | 3.8 |
| 581.5 | 9,137.5 | 4,178.2 | 0.8 | -- | 0.1 | -- | 3.2 | |
| 1,156.1 | 9,544.7 | 1,006.9 | 160.4 | 20.4 | 12.6 | 60.1 | 7.3 | |
| 517.3 | 12,509.2 | 4,460.0 | 479.1 | 16.4 | 14.4 | 26.1 | 3.5 | |
| 408.6 | 5,067.7 | 1,859.8 | 90.8 | 10.4 | 7.4 | 55.8 | 4.0 | |
| 912.6 | 5,111.6 | 1,191.6 | 127.4 | 13.3 | 13.7 | 39.9 | 5.3 | |
| 900.1 | 2,203.2 | 356.3 | 100.9 | 25.0 | 13.3 | 21.8 | 2.8 | |
| 266.1 | 2,376.3 | 780.4 | 63.4 | 12.6 | 12 | 36 | 3.8 | |
| 162.8 | 5,314.0 | 71.8 | -342.5 | -467.5 | -- | -- | -24.5 | |
| 988.7 | 2,935.1 | 245.3 | -50.8 | -18.5 | -40.5 | -- | 9.9 |
No Review & Analysis are available.
Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active... pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acidic and allied products comprising sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India. Read more
Incorporated
2019
Chairman
Rashesh C Gogri
Managing Director
Narendra J Salvi
Headquarters
Vapi, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsGrant Of Options Under PSOP Scheme 2023
10-May-2025Results For The Financial Year Ended 31.03.2025
10-May-2025
The total asset value of Aarti Pharmalabs Ltd stood at ₹ 2,906 Cr as on 31-Mar-25
The share price of Aarti Pharmalabs Ltd is ₹845.35 (NSE) and ₹844.75 (BSE) as of 20-May-2025 12:29 IST. Aarti Pharmalabs Ltd has given a return of 37.42% in the last 1 years.
Aarti Pharmalabs Ltd has a market capitalisation of ₹ 7,657 Cr as on 20-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Aarti Pharmalabs Ltd is 3.85 times as on 20-May-2025, a 1% discount to its peers’ median range of 3.90 times.
The P/E ratio of Aarti Pharmalabs Ltd is 28.11 times as on 20-May-2025, a 32% discount to its peers’ median range of 41.45 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Aarti Pharmalabs Ltd and enter the required number of quantities and click on buy to purchase the shares of Aarti Pharmalabs Ltd.
Aarti Pharmalabs Limited, together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system (CNS) agents, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acidic and allied products comprising sulphuric acid, sulphur trioxide, oleum, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is based in Mumbai, India.
The prominent promoters of Aarti Pharmalabs Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Rashesh Chandrakant Gogri |
4.23%
|
|
Jaya Chandrakant Gogri |
3.54%
|
|
Anushakti Enterprise Private Limited |
3.3%
|
|
LABDHI BUSINESS TRUST (Saswat Trusteeship Private Limited) |
3.14%
|
The chairman of the company is Rashesh C Gogri, and the managing director is Narendra J Salvi.
There is no promoter pledging in Aarti Pharmalabs Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
12,274
|
|
|
9,199
|
|
|
8,602
|
|
|
5,277
|
|
|
5,231
|
|
|
4,794
|
|
|
2,875
|
|
|
2,299
|
|
|
2,147
|
| Aarti Pharmalabs Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
14.16
|
|
Operating margin(%)
|
17.85
|
|
Net Margin(%)
|
12.82
|
|
Dividend yield(%)
|
0.58
|
Yes, TTM profit after tax of Aarti Pharmalabs Ltd was ₹272 Cr.
₹-9.90
(
